FDA Orange Book · active-ingredient family
Ixazomib citrate
Ixazomib citrate is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:NINLARO · NDA 208462
1
Brand (NDA)
0
Generics (ANDA)
7
Listed patents
0
Exclusivity periods
Brand (NDA) products · capsule
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| NINLARORLD×3 | TAKEDA PHARMS USA | NDA 208462 | — | Nov 20, 2015 |
Listed patents (7)
| Patent | Expires | In | Type |
|---|---|---|---|
| 8871745 | Aug 06, 2027 | in 1 yr 2 mo | U-2434 |
| 8003819 | Aug 06, 2027 | in 1 yr 2 mo | SubstanceProductU-2434 |
| 8530694 | Aug 06, 2027 | in 1 yr 2 mo | SubstanceProductU-2434 |
| 7687662 | Aug 06, 2027 | in 1 yr 2 mo | SubstanceProduct |
| 9175017 | Jun 16, 2029 | in 3 yr | U-2434 |
| 8859504 | Jun 16, 2029 | in 3 yr | SubstanceProduct |
| 7442830 | Nov 20, 2029 | in 3 yr 6 mo | SubstanceProductU-2434 |
Ixazomib citrate — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
